The anti-tumor effects of statins in HCC have been attributed to the inhibition of MYC oncogene (Cao et al., 2011), protein kinase B (AKT) (Roudier et al., 2006; Ghalali et al., 2017), and NF-κB pathways, as well as decreased production of pro-inflammatory cytokines (Wang et al., 2006; Li et al., 2020a). The gene discussed is AKT1; the disease is hepatocellular carcinoma.